Stocksigma LogoStocksigma Logo

Gujarat Themis Biosyn Reports Q2 FY27 Results and Strategic Acquisitions

In Q2 FY27, Gujarat Themis Biosyn posted standalone revenue of INR 47.5 Cr, up 12.1% YoY, while EBITDA dropped 15.3% YoY to INR 17.7 Cr (37.4% margin) and

Gujarat Themis Biosyn Reports Q2 FY27 Results and Strategic Acquisitions

Gujarat Themis Biosyn Ltd 路 Investor Presentation 路 16 Nov 2026, 12:02 am

Gujarat Themis Biosyn Reports Q2 FY27 Results and Strategic Acquisitions In Q2 FY27, Gujarat Themis Biosyn posted standalone revenue of INR 47.5 Cr, up 12.1% YoY, while EBITDA dropped 15.3% YoY to INR 17.7 Cr (37.4% margin) and PAT fell 40.6% YoY to INR 8.5 Cr due to initial fermentation facility commissioning costs and financing expenses. H1 FY27 standalone revenue reached INR 91.2 Cr (+16.7% YoY) with EBITDA of INR 38.5 Cr (+10.5% YoY). The company completed the acquisition of MicroBiopharm Japan for JPY 21.5 Bn (~INR 1,300 Cr) and agreed to acquire Sanofi鈥檚 anti-infective portfolio (~EUR 158 Mn).

Original exchange filing (PDF)

More announcements from Gujarat Themis Biosyn Ltd

All Gujarat Themis Biosyn Ltd announcements